Product Data Sheet



Fentiazac

Cat. No.: HY-118752 CAS No.: 18046-21-4 Molecular Formula: $C_{17}H_{12}CINO_2S$

Molecular Weight: 329.8 Others Target: Pathway: Others

Storage: Powder -20°C 3 years

2 years

-80°C 6 months In solvent

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (303.21 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.0321 mL	15.1607 mL	30.3214 mL
	5 mM	0.6064 mL	3.0321 mL	6.0643 mL
	10 mM	0.3032 mL	1.5161 mL	3.0321 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.58 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: ≥ 2.5 mg/mL (7.58 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.58 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Fentiazac, alkanoic acid derivative, is an orally active non-steroidal anti-inflammatory agent, with analgesic, antipyretic and platelet anti-aggregation activity. Fentiazac can be used to research inflammatory diseases such as rheumatoid arthritis, osteoarthritis and tendinitis ^{[1][2][3]} .
In Vivo	Fentiazac is well tolerated after repeated oral administration in rats, monkeys and dogs; and no significant modifications in the heart and bone marrow function, as well as blood chemistry ^[1] . Tolerance of Fentiazac in rat, monkey and $dog^{[1]}$.

Tolerant dosage	Tolerant administration day
0-50 mg/kg/day	90 days
40 mg/kg/day	90 days
0-30 mg/kg/day	180 days
0-8 mg/kg/day	79 to 93 days
16.6 mg/kg/day	180 days
	0-50 mg/kg/day 40 mg/kg/day 0-30 mg/kg/day 0-8 mg/kg/day

REFERENCES

[1]. Emilio Marmo, et al. Experimental and clinical pharmacology of fentiazac, a new, non-steroidal anti-inflammatory agent. Current Medical Research and Opinion. Volume 6, 1979 - Issue sup2.

[2]. Gabor Katona, et al. Efficacy and tolerability of fentiazac in rheumatoid arthritis: Double-blind study versus indomethacin. Current Medical Research and Opinion. Volume 6, 1979 - Issue sup2.

[3]. Famaey JP, Gaci O, Ginsberg F. Fentiazac in the treatment of osteoarthritis and tendinitis. Curr Med Res Opin. 1983;8(9):675-81.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA